The widespread use of calcium carbonate as a phosphate binder is limited by its tendency to develop hypercalcemia in some patients using effective dosages needed to control hyperphosphatemia. Most common continuous ambulatory peritoneal dialysis (CAPD) regimens using dialysis solutions containing 3.5 mEqlL of calcium result in net absorption of calcium from the dialysis solution and, hence limit the amount of oral calcium that can be administered. Peritoneal dialysis solutions with reduced calcium levels are needed for effective use of CaCO3 to control hyperphosphatemia in some dialysis patients.
CoburnJ.W., SlatopolskyE.Vitamin D, parathyroid hormone and renal osteodystrophy. In: BrennerB.M., RectorF.C., eds. The Kidney.Philadelphia: W. B. Saunders;1986: 1657–1729.
2.
FournierA.E., ArnaudC.D., JohnsonW.J.Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. 11. Factors affecting serum immunoreactive parathyroid hormone.J Clin Invest.1971; 50: 599–605.
3.
SaluskyIll, CoburnJ.W., PaunierL.Role of aluminum hydroxide in raising serum aluminum levels in children undergoing continuous ambulatory peritoneal dialysis (CAPD).J Pediat.1984; 105: 717–720.
4.
FelsenfeldA.J., GutmanR.A., LlachF.Osteomalacia in chronic renal failure: A syndrome previously reported only with maintenance dialysis.Am J Nephrol.1982; 2: 147–152.
5.
SedmanA.B., MillerN.L., WaradyB.A.Aluminum loading in children with chronic renal failure.Kidney Int.1984; 26: 201–204.
6.
AndreoliS.P., BriggsJ.D., JunorB.J.R.Aluminum intoxication from aluminum-containing phosphate binders in children with azotemia not undergoing dialysis.N Engl J Med.1984; 310: 1079–1084.
7.
KayeM.Oral aluminum toxicity in a non-dialyzed patient with renal failure.Clin Nephrol.1983; 20: 208–211.
8.
WillsM.R., SavoryJ.Aluminum poisoning: Dialysis en cephalopathy, osteomalacia, and anemia.Lancet.1983; 2: 29–34.
9.
MehtaR.P.Encephalopathy in chronic renal failure appearing before the start of dialysis.Can Med Assn J.1979; 120: 1112–1114.
10.
NathanE., PenersonS.E.Dialysis encephalopathy in a nondialyzed uremic boy treated with aluminum hydroxide orally.Acta Paediat Scand.1980; 69: 793–796.
11.
ClarksonE.M., McDonaldS.J., De WardnerH.E.The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure.Clin Sci.1966; 30: 425–438.
12.
RamirezJ.A., EmmettM., WhiteM.G.The absorption of dietary phosphorus and calcium in hemodialysis patients.Kidney Int.1986; 30: 753–759.
13.
SaluskyI.B., CoburnJ.W., FoleyJ.Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysis.J Pediat.1986; 108: 767–770.
14.
HerczG., KrautJ.A., AndressD.A.Use of calcium carbonate as a phosphate binder in dialysis patients.Miner Electrolyte Metab.1986; 12: 314–319.
15.
SlatopolskyE., WeertsC., Lopez HilkerS.Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis.N Engl J Med.1986; 315: 157–161.
16.
SteinH.D., YudisM., SirotaR.A.Calcium carbonate as a phosphate binder.N Engl J Med.1987; 316: 109–110.
17.
ClarksonE.M., EastwoodJ.B., KoutsaimanisK.G.Net intestinal absorption of calcium in patients with chronic renal failure.Kidney Int.1973; 3: 258–263.
18.
SheikhM.S., MaguireJ.A., EmmettM.Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study.J Clin Invest.1989; 83: 66–73.
19.
SchillerL.R., Santa AnaC.A., SheikhM.S.Effect of the time of administration of calcium acetate on phosphorus binding.N Engl J Med.1989; 320: 1110–1113.
20.
ReckerR.R., SavilleP.D.Calcium absorption in renal failure: Its relationship to blood urea nitrogen, dietary calcium intake, time on dialysis, and other variables.J Lab Clin Med.1971; 78: 380–388.
21.
BlumenkrantzM.J., KoppleJ.D., MoranJ.K.Metabolic balance studies and dietary protein requirements in patients undergoing continuous ambulatory.Kidney Int.1982; 21: 849–861.
DelmezJ.A., SlatopolskyE., MartinK.J.Minerals, vitamin D and parathyroid hormone in continuous ambulatory peritoneal dialysis.Kidney Int.1982; 21: 862–867.
24.
ParkerA., NolphK.D.Magnesium and calcium mass transfer during continuous ambulatory peritoneal dialysis.Trans Am Soc Artif Intern Organs.1980; 26: 194–196.
25.
KwongM.B.L., LeeJ.S.K., ChanM.K.Transperitoneal calcium and magnesium transfer during an 8-hour dialysis.Perit Dial Bull.1987; 7: 85–89.
26.
GuytonA.C.Textbook of medical physiology.Philadelphia: W. B. Saunders Company; 1981.
27.
MactierR.A., TwardowskiZ.J.Influence of dwell time, osmolality, and volume of exchanges on solute transfer and ultrafiltration in peritoneal dialysis.Seminar Dial.1988; 1: 40–49.
28.
GokalR.Historical development and clinical use of continuous ambulatory peritoneal dialysis. In: GokalR., ed. Continuous Ambulatory Peritoneal Dialysis.Edinburgh: Churchill Livingstone; 1986: 1–13.
